Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Combo Products Review Transformation Begins

Executive Summary

Pilot project sets timelines for lead and consulting centers that will feed into more substantial changes in PDUFA VI.

You may also be interested in...



FDA Tussles With Combination Products, Fires Up Oncology Center Of Excellence

FDA officials discuss difficulties dealing with complex combination products, the future of the agency's Centers, and promotion of industry collaboration at DIA meeting.

FDA's Pazdur To Retain Drug Approval Duties In Oncology Center Of Excellence

Center for Drug Evaluation and Research's long-time director of oncology/hematology products office will continue as signatory on drug reviews even after new Cancer Moonshot-driven structure takes effect.

EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review

House and Senate letters ask why Mylan's autoinjector doesn't have competition, offering a preview of potential debates on renewal of the generic user fee program.

Related Content

Topics

UsernamePublicRestriction

Register

PS118998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel